Gara Jalqabaatti › Diffuse Large B-Cell Lymphoma
Qorannoo klinikaalii Diffuse Large B-Cell Lymphoma Ameerikaa Keessatti hirmaatuu
Qorannoo 101 Diffuse Large B-Cell Lymphoma f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- New York City, NYQorannoo 21
- Baldwin Park, CAQorannoo 19
- Chicago, ILQorannoo 18
- Houston, TXQorannoo 17
- Los Angeles, CAQorannoo 17
- Milwaukee, WIQorannoo 16
- Boston, MAQorannoo 16
- Nashville, TNQorannoo 15
- Philadelphia, PAQorannoo 15
- Portland, ORQorannoo 15
- Durham, NCQorannoo 14
- Dallas, TXQorannoo 13
- Washington, DCQorannoo 12
- Seattle, WAQorannoo 12
- Salt Lake City, UTQorannoo 12
- Cincinnati, OHQorannoo 11
- Cleveland, OHQorannoo 11
- Denver, COQorannoo 11
- Rochester, MNQorannoo 10
- Richmond, VAQorannoo 10
- Atlanta, GAQorannoo 10
- Cedar Rapids, IAQorannoo 9
- Edison, NJQorannoo 9
- Omaha, NEQorannoo 9
- Columbus, OHQorannoo 9
- Greenburgh, NYQorannoo 8
- Jacksonville, FLQorannoo 8
- Grand Rapids, MIQorannoo 8
- Louisville, KYQorannoo 8
- San Francisco, CAQorannoo 8
- San Antonio, TXQorannoo 8
- New Haven, CTQorannoo 8
- St. Louis, MOQorannoo 8
- Sacramento, CAQorannoo 8
- Miami, FLQorannoo 7
- Kansas City, MOQorannoo 7
- Indianapolis, INQorannoo 7
- Aurora, COQorannoo 7
- Charlottesville, VAQorannoo 7
- Buffalo, NYQorannoo 6
Naannoon
- AlabamaQorannoo 4
- ArizonaQorannoo 13
- ArkansasQorannoo 4
- CaliforniaQorannoo 42
- ColoradoQorannoo 19
- ConnecticutQorannoo 8
- Distaarikii KoloombiyaaQorannoo 4
- FloridaQorannoo 23
- GeorgiaQorannoo 15
- IdahoQorannoo 4
- IllinoisQorannoo 22
- IndianaQorannoo 9
- IowaQorannoo 11
- KansasQorannoo 7
- KentuckyQorannoo 11
- LouisianaQorannoo 6
- MarylandQorannoo 13
- MassachusettsQorannoo 16
- MichiganQorannoo 15
- MinnesotaQorannoo 16
- MissouriQorannoo 8
- MontanaQorannoo 4
- NebraskaQorannoo 9
- NevadaQorannoo 3
- New JerseyQorannoo 13
- New MexicoQorannoo 3
- New YorkQorannoo 31
- North CarolinaQorannoo 20
- North DakotaQorannoo 4
- OhioQorannoo 23
- OklahomaQorannoo 5
- OregonQorannoo 15
- PennsylvaniaQorannoo 19
- South CarolinaQorannoo 4
- South DakotaQorannoo 3
- TennesseeQorannoo 19
- TexasQorannoo 29
- UtahQorannoo 14
- VirginiaQorannoo 17
- WashingtonQorannoo 17
- WisconsinQorannoo 19
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05006716Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06834373Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06500273Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06863402Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07763210Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06649812Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 0 hanga 38 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06131801Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT06977711Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 65 hanga 99 · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT05952024Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT03223610A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05139017A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06717347A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07519772A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06091865Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Namoota walitti qabaa jiraSadarkaa 1/2
6 Months – 25 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06395103Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT04002947Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT05757219A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT05272384Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.